These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32737994)

  • 1. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
    Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
    J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma.
    Yokoyama D; Hisamori S; Deguchi Y; Nishigori T; Okabe H; Kanaya S; Manaka D; Kadokawa Y; Hata H; Minamiguchi S; Tsunoda S; Obama K; Sakai Y
    Sci Rep; 2021 Apr; 11(1):9013. PubMed ID: 33907203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
    Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
    Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma.
    Tanaka S; Mori M; Akiyoshi T; Tanaka Y; Mafune K; Wands JR; Sugimachi K
    Cancer Res; 1997 Jan; 57(1):28-31. PubMed ID: 8988034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
    Nadler Y; González AM; Camp RL; Rimm DL; Kluger HM; Kluger Y
    Ann Oncol; 2010 Mar; 21(3):466-473. PubMed ID: 19717535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCF12-regulated GRB7 facilitates the HER2+ breast cancer progression by activating Notch1 signaling pathway.
    Wang G; Wu Y; Su Y; Qu N; Chen B; Zhou D; Yuan L; Yin M; Liu M; Zhou W
    J Transl Med; 2024 Aug; 22(1):745. PubMed ID: 39113057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells.
    Chu PY; Li TK; Ding ST; Lai IR; Shen TL
    J Biol Chem; 2010 Sep; 285(38):29279-85. PubMed ID: 20622016
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
    Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
    J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
    Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
    Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
    Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
    Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
    Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
    J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
    Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
    J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.
    Hedner C; Tran L; Borg D; Nodin B; Jirström K; Eberhard J
    Histopathology; 2016 Jan; 68(2):230-40. PubMed ID: 26016514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.